**For Immediate Release**

# DIMERIX RECEIVES FIRST DEVELOPMENT MILESTONE PAYMENT FROM FUSO

- Dimerix has received the first development milestone payment of ¥400 million (~AU$4.2 million[1]) from Japanese partner, FUSO Pharmaceutical Industries Ltd. following the opening of clinical sites in Japan
- Sites opening in Japan will aid recruitment of ACTION3 clinical trial, with approximately 20 patients to be recruited to support potential approval in Japan[2]
- Dimerix may receive from FUSO up to ¥10.5 billion (~AU$107 million[2] in total) in upfront, development and sales milestone payments, plus royalties:
  - ✓ ¥300 million (~AU$3.1 million[3]) received following execution of the agreement
  - ✓ ¥400 million (~AU$4.2 million[1]) received following first development milestone of first clinical site initiation in Japan
  - up to ¥3 billion (~AU$30.6 million[2]) in further potential development milestones
  - up to ¥6.8 billion (~AU$69.4 million[2]) in potential sales milestones
  - 15-20% royalties on net sales
- FUSO licensing agreement for Japan is one of four regional licensing deals executed for DMX-200:
  - ✓ Over AU$65 million has already been received to date across upfront and development milestone payments
  - Collectively the license deals may deliver up to ~AU$1.4 billion[4] in total upfront payments and potential milestone payments, plus royalties on net sales
- Dimerix continues to pursue licensing opportunities with potential partners in territories not already licensed

MELBOURNE, Australia, 30 June 2025: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, today announced that it has received the first development milestone payment of ¥400 million (~AU$4.2 million[1]) from FUSO Pharmaceutical Industries Ltd, the exclusive licensee of DMX-200 for FSGS in Japan.[2] Under the agreement, FUSO has been granted exclusive rights to commercialise DMX-200 for FSGS in Japan.

Under the FUSO agreement, Dimerix may become eligible to receive further potential success-based development and regulatory milestone payments of up to ¥3 billion (~AU$30.6 million[2]) in further potential development milestones, up to ¥6.8 billion (~AU$69.4 million[2]) in potential sales milestones and tiered royalties from fifteen to twenty percent of DMX 200 net sales in Japan

Dimerix now has four high quality partners across multiple territories, providing strong support for Dimerix in advancing and commercialising DMX-200 as a potential new treatment for FSGS. Collectively across all licences, Dimerix may become eligible for up to ~AU$1.4 billion[4] in total upfront payments and potential milestone payments, plus royalties on net sales. Dimerix continues to pursue licensing opportunities with potential partners in territories not already licensed including China.



**Dimerix HQ**
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com

**About ACTION3 FSGS Phase 3 Study**

The Phase 3 study, which is titled "Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis", or ACTION3 for short, is a pivotal (Phase 3), multi-centre, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients will be randomized to receive either DMX-200 (120 mg capsule twice daily) or placebo.

The single Phase 3 trial in FSGS patients has two interim analysis points built in that are designed to capture evidence of proteinuria and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval. Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

For further information, please visit our website at www.dimerix.com or contact:


Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au


Follow us on **LinkedIn** and **Twitter**

*Authorised for lodgement by the Board of the Company*

**—END—**

**About Dimerix Limited**

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for respiratory disease. DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. For more information, please visit the company's website at www.dimerix.com and follow on X and LinkedIn.

**About DMX-200**

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to Orphan Drug Designation granted by the FDA in the United States.

**About FSGS**

FSGS is a rare, serious kidney disorder characterized by progressive scarring (sclerosis) in parts of the glomeruli—the kidney's filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children.[5] There are no therapies specifically approved for FSGS in the U.S., and management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,[6] underscoring the urgent need for new, disease-modifying treatments.

**Dimerix Forward Looking Statement**

This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, along with those factors outlined in the most recent Dimerix Limited Annual Report.

**References**

1 *Using XE exchange rate of 100 Japanese Yen = 1.05 AUD as at 26 June 2025, before tax*
2 *ASX release 7 January 2025*
3 *ASX release 4 March 2025*
4 *Based on XE exchange rates & further terms outlined in ASX Announcements on 5 October 2023, 27 May 2024, 07 January 2025, and 01 May 2025;*
5 *Nephcure FSGS Facts (https://nephcure.org/)*
6 *Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669*